# Solid Tumor Molecular Testing Requisition

**Pathology Laboratory Associates, Inc.**
4142 South Mingo Road, Tulsa, OK 74146
Fax: 918.416.0506 Phone: 918.417.6400

**Client Name:** _____
**Account:** _____

*****Please return this form with Treatment Notes/Clinicals from last 2-4 appoinments, along with patient demographic information*****

## I. PATIENT INFORMATION (Name on requisition must match name on speciment exactly.)

| Last Name | First Name | Middle | Date of Birth (MM/DD/YYYY) | Patient MRN: |
|---|---|---|---|---|
| | | | | |

| Patient Address | City | State | Zip Code | ☐ Male ☐ Female | Home Phone: |
|---|---|---|---|---|---|
| | | | | | |

## II. BILLING INFORMATION

| Insurance Company | Policy Number | Group Number |
|---|---|---|
| | | |

## III. SPECIMEN INFORMATION (*ALL FIELDS IN THIS SECTION ARE REQUIRED*)

| Collection Date | Collection Time | Case number | Diagnosis Codes: | ☐ **Inpatient at time of collection** ☐ **Outpatient at time of collection** |
|---|---|---|---|---|
| | | | | |

## IV. CLIENT/PHYSICIAN INFORMATION

| Requesting Physician/(Attending Physician if needed) | NPI Number or Equivalent | Facility/Organization |
|---|---|---|
| | | |

| Fax Number | Phone Number | Consulting Copy to Physician(s) |
|---|---|---|
| | | |

| ******Ordering Provider Signature:** | **Date:** |
|---|---|
| | |

## V. NEXT GENERATION SEQUENCING (NGS)

☐ **NGS Solid Tumor Panel** (See gene list below.)

## VI. TEST ORDERS FOR INIVIDUAL SELECTION:

- ☐ **ALK (FISH)**
- ☐ **B Cell Clonality/IGH (PCR)**
- ☐ **BRAF (Molecular)**
- ☐ **EGFR**
- ☐ **ER/PR/Ki67 Expression (IHC)**
- ☐ **FOLR1**
- ☐ **Her2 IHC with reflex to FISH if indicated***
- ☐ **IDH1 & IDH2**
- ☐ **KIT Mutation for GIST**
- ☐ **KIT Mutation for Mastocytosis**
- ☐ **KIT Mutation for Melanoma (exons 1, 13 and 17)**
- ☐ **MDM2**
- ☐ **MMR Mismatch Repair (IHC) (MLH1/MSH2/MSH6/PMS2)***
- ☐ **MYC FISH with reflex to BCL2 & BCL6 (FISH)**
- ☐ **NRAS Mutation (PCR)**
- ☐ **PDL1 (IHC): Select the desired test below**
  - ☐ 22C3 CPS Pembrolizumab (KEYTRUDA)
  - ☐ 22C3 TPS Pembrolizumab (KEYTRUDA) and Cemiplimab (LIBTAYO)
  - ☐ **28-8 Nivolumab (OPDIVO)**
  - ☐ **SP263 TPS Atezolizumab (TECENTRIQ)**
- ☐ **PIK3CA Mutation (PCR)**
- ☐ **RET (FISH)**
- ☐ **ROS1 (FISH)**
- ☐ **T-Cell Receptor (PCR)**
- ☐ **Tert, MGMT, 1P19q – Gliomas**

*HER2 IHC, HER2 (ERBB2) FISH and ER/PR IHC will be added on cases of breast cancer at initial diagnosis and diseas progression after greater than one year.
*Mismatch Repair (IHC) testing will be added on cases of colorectal cancer or endometrial cancer at initial diagnosis.

## Genes Included in Solid Tumor NGS Panel

**DNA HOTSPOTS (45)**

| | | | | | |
|---|---|---|---|---|---|
| *AKT1* | *CDKN2A* | *FGFR1* | *HRAS* | *MTOR* | *RAF1* |
| *AKT2* | *CHEK2* | *FGFR2* | *IDH1* | *NRAS* | *RET* |
| *AKT3* | *CTNNB1* | *FGFR3* | *IDH2* | *NTRK1* | *ROS1* |
| *ALK* | *EGFR* | *FGFR4* | *KIT* | *NTRK2* | *SMO* |
| *AR* | *ERBB2/* HER2 | *FLT3* | *KRAS* | *NTRK3* | *TP53* |
| *ARAF* | *ERBB3* | *GNA11* | *MAP2K1* | *PDGFRA* | *{ }* |
| *BRAF* | *ERBB4* | *GNAQ* | *MAP2K2* | *PIK3CA* | *{ }* |
| *CDK4* | *ESR1* | *GNAS* | *MET* | *PTEN* | *{ }* |

**CNVs (14)**

| | |
|---|---|
| *ALK* | *FGFR1* |
| *AR* | *FGFR2* |
| *CD274* | *FGFR3* |
| *EGFR* | *KRAS* |
| *ERBB2* | *MET* |
| *ERBB3* | *PIK3CA* |
| *CDKN2A* | *PTEN* |
| *{ }* | *{ }* |

**INTER-GENIC FUSIONS (16)**

| | | | |
|---|---|---|---|
| *ALK* | *FGFR3* | *RET* | *AR* |
| *BRAF* | *MET* | *ROS1* | *EGFR* |
| *ESR1* | *NRG1* | *RSPO2* | *MET* |
| *FGFR1* | *NTRK1* | *RSPO3* | *{ }* |
| *FGFR2* | *NTRK2* | *{ }* | *{ }* |
| *{ }* | *NTRK3* | *{ }* | *{ }* |
| *{ }* | *NUTM1* | *{ }* | *{ }* |
| *{ }* | *{ }* | *{ }* | *{ }* |

**INTRA-GENIC FUSIONS (16)**

**We are utilizing the ThermoFisher Genexus™ instrumentation with the Oncomine Precision Assay™ (OPA) and bioinformatics that is updated monthly to include reporting of the latest developments in treatment options and clinical trials. The OPA analyzes 78 variants including mutations, copy number variants and fusion variants across 50 key genes including cancer drivers, tumor suppressor genes and resistance mutations. Novel fusion detection chemistry allows detection of as few as 5 gene copies and requires the least amount of nucleic acid input compared to other NGS platforms, thus "quantity not sufficient" results will be significantly reduced. Tumor types that may benefit most from NGS include, but are not limited to, NSCLC, Colorectal Cancer, Melanoma, Breast Cancer, Gastric Cancer, Cervical Cancer and Unspecified Solid Tumors.**

**Sample type: Formalin Fixed Paraffin Embedded Tissue (FFPE) with at least 5% tumor**